3/22
09:08 am
shph
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update [Yahoo! Finance]
Medium
Report
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update [Yahoo! Finance]
3/22
09:00 am
shph
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
Medium
Report
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
3/5
09:00 am
shph
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
Low
Report
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024
2/13
08:10 am
shph
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering [Yahoo! Finance]
Medium
Report
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering [Yahoo! Finance]
2/13
08:00 am
shph
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
High
Report
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
1/23
04:48 pm
shph
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 [Yahoo! Finance]
Medium
Report
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 [Yahoo! Finance]
1/23
04:30 pm
shph
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Medium
Report
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
1/15
07:35 am
shph
Active Pharmaceutical Ingredients Market To Reach USD 346.4 Billion By 2032 at CAGR 8.7%| DataHorizzon Research [Yahoo! Finance]
Low
Report
Active Pharmaceutical Ingredients Market To Reach USD 346.4 Billion By 2032 at CAGR 8.7%| DataHorizzon Research [Yahoo! Finance]
1/8
09:12 am
shph
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma [Yahoo! Finance]
High
Report
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma [Yahoo! Finance]
1/8
09:00 am
shph
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
High
Report
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma